RIAS
CYTK icon

Rachor Investment Advisory Services’s Cytokinetics CYTK Stock Holding History

Rachor Investment Advisory Services’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-36
Closed -$2.37K – 266
2026
Q1 		$2.37K Sell
36
-8
-18% -$508 ﹤0.01% 237
2025
Q4 		$2.8K Buy
+44
New +$2.74K ﹤0.01% 210

Other funds holding CYTK

Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
EOJOAM
E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return

Rachor Investment Advisory Services's CYTK Position: Q2 2026 in Review

Rachor Investment Advisory Services sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 36 shares — an estimated $2.37K sold.

Rachor Investment Advisory Services first reported a position in CYTK in Q4 2025 and held it in 2 quarters. The position peaked at $2.8K in Q4 2025. 163 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Rachor Investment Advisory Services reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
  • Rachor Investment Advisory Services sold 36 Cytokinetics shares in Q2 2026, an estimated $2.37K.
  • Rachor Investment Advisory Services first reported a position in Cytokinetics in Q4 2025 and held it in 2 quarters.
  • Rachor Investment Advisory Services's Cytokinetics position peaked at $2.8K in Q4 2025.
  • 163 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Rachor Investment Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.